A former biotechnology executive failed to convince a federal judge Monday that he’s entitled to a new trial or judgment in his favor on insider trading claims following a jury verdict for the SEC in April.
The closely watched civil trial in federal court in California was the regulator’s first enforcement action targeting so-called shadow trading, in which a company insider uses nonpublic information to trade in a competitor’s stock.
Former Medivation Inc. executive Matthew Panuwat received a fair trial and doesn’t have the law on his side, Judge William Orrick said for the US District Court for the Northern ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.